Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1

Status

Recruiting 4

Sponsor Class

OTHER 4INDUSTRY 3

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 3Sarcoma 1Gynecologic 1

Conditions

Breast Neoplasms 2Sarcoma, Endometrial Stromal 1Perivascular Epithelioid Cell Neoplasms 1Advanced Breast Cancer 1Adenosarcoma of the uterus 1

Interventions

pembrolizumab 603Cyclophosphamide 545Magnetic Resonance Spectroscopy 527Radiotherapy 513Specimen Handling 505Nivolumab 411Cisplatin 381Carboplatin 369Biopsy 305Blood Specimen Collection 304Radiosurgery 290Paclitaxel 281Gemcitabine 271Surveys and Questionnaires 269Standard of Care 267fludarabine 263Drug Therapy 263Dexamethasone 263Bevacizumab 252venetoclax 251Oxaliplatin 209Capecitabine 199Rituximab 198Radiation 191Ipilimumab 188Fluorouracil 188durvalumab 185Doxorubicin 178Etoposide 177atezolizumab 172

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × RAD1901 × 1 year × Clear all
NCT07467772 2026-05-22

Ph 2 Elacestrant in ER Positive Uterine Sarcomas

Dana-Farber Cancer Institute

Phase 2 Recruiting
30 enrolled
GynecologicSarcoma

Adenosarcoma of the uterus, Sarcoma, Endometrial Stromal, Perivascular Epithelioid Cell Neoplasms

NCT07198724 2026-04-09

ERADICATE

Dana-Farber Cancer Institute

Phase 1/2 Recruiting
65 enrolled
Breast

Breast Neoplasms

NCT06382948 2026-04-03

ADELA

MedSIR

Phase 3 Recruiting
240 enrolled
Breast

Advanced Breast Cancer

NCT07222215 2026-01-22

CAPELA

Dana-Farber Cancer Institute

Phase 2 Recruiting
297 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡